Literature DB >> 11371997

Risks in new drug development: approval success rates for investigational drugs.

J A Dimasi1.   

Abstract

Mesh:

Substances:

Year:  2001        PMID: 11371997     DOI: 10.1067/mcp.2001.115446

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  53 in total

1.  The value of improving the productivity of the drug development process: faster times and better decisions.

Authors:  Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline.

Authors:  Amanda G Paulovich; Jeffrey R Whiteaker; Andrew N Hoofnagle; Pei Wang
Journal:  Proteomics Clin Appl       Date:  2008-10-01       Impact factor: 3.494

3.  Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials.

Authors:  John H Powers
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

Review 4.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

5.  The economics of follow-on drug research and development: trends in entry rates and the timing of development.

Authors:  Joseph A DiMasi; Cherie Paquette
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  Data supplementation: a pharmacokinetic/pharmacodynamic knowledge creation approach for characterizing an unexplored region of the response surface.

Authors:  Ene I Ette; Hui-May Chu; Christopher J Godfrey
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

7.  The new medical technologies and the organizations of medical science and treatment.

Authors:  Mary L Fennell
Journal:  Health Serv Res       Date:  2008-02       Impact factor: 3.402

8.  Waiting for reimbursement of new medicines in Canada: it's time for a rethink.

Authors:  Brett J Skinner
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Early human studies of investigational agents: dose or microdose?

Authors:  Lionel D Lewis
Journal:  Br J Clin Pharmacol       Date:  2009-03       Impact factor: 4.335

Review 10.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.